Deletions affecting the long arm of chromosome 6 (6q) are among the most commonly observed chromosomal aberrations in lymphoid malignancies and have been identified as adverse prognostic factor in subsets of tumors. Whereas at least two regions of minimal deletion have been established, one in 6q21-q23 and another in 6q25-q27, no tumor suppressor gene that might be involved in the pathogenesis of lymphoid malignancies has been so far identified from these segments. For B cell chronic lymphocytic leukemia (B-CLL) conflicting data have been reported regarding the incidence and prognostic significance of 6q deletions. In the current study we have used two YAC clones mapping to deletion regions in bands 6q21 and 6q27 as probes for fluorescence in situ hybridization (FISH) in a large series of B-CLL cases to analyze the incidence, localization and clinical significance of 6q aberrations. Among 285 patients with B-CLL studied we identified 21 cases (7%) with 6q deletions. All deletions were found with the probe mapping to 6q21 while the 6q27 region was deleted only in a third of these cases. Analysis of the clinical characteristics and laboratory parameters showed that the patients with 6q deletions had higher white blood cell counts and more extensive lymphadenopathy. However, the overall survival and the treatmentfree intervals were similar in the two groups. We conclude that deletions in 6q21 occur in 7% of B-CLL and identify a subgroup of patients characterized by a larger tumor mass but no inferior outcome.
Introduction
Deletions involving the long arm of chromosome 6 (6q) are among the most common structural aberrations leading to a loss of chromosomal material in lymphoproliferative disorders and non-Hodgkin's lymphoma (NHL). 1, 2 Distinct minimal deletion regions have been identified in 6q indicating the possible location of tumor suppressor genes that might be involved in the pathogenesis. Gaidano et al 3 found 6q deletions by restriction fragment length polymorphism analysis at a frequency of 22.5% in a heterogeneous series of 71 patients with B-NHL and observed two deletion cluster regions, one in 6q21-q23 and one in 6q25-q27. Another commonly deleted segment at bands 6q11-q21 was identified in B-NHL by fluorescence in situ hybridization (FISH). 4 Comparing 6q deletions found by chromosome banding in 94 patients with B-NHL, Offit et al 5 identified three deletion clusters affecting 6q21, 6q23 and 6q25-27 which were linked to the histologic subgroups of high-grade, low-grade and intermediate-grade NHL, respectively. In another study by chromosome banding the deletion del(6)(q21q23) was the most common cytogenetic abnormality in small lymphocytic NHL at a frequency of 26%. In B cell chronic lymphocytic leukemia (B-CLL) structural abnormalities of 6q were found in 6% of evaluable cases by chromosome banding analysis. 7 However, it has been demonstrated that the frequency of genetic aberrations in B-CLL is underestimated by chromosome banding and that molecular cytogenetic analysis by means of FISH on interphase cells ('interphase cytogenetics') improves the sensitivity for the detection of genetic abnormalities in B-CLL. 8 A recent FISH study with probes mapping to 6q23-q24 identified deletions of this chromosome region in four of nine B-CLL samples tested, indicating a higher incidence of 6q deletions than previously thought. 9 The significance of 6q deletions for the clinical course of NHL has been evaluated in chromosome banding studies. Tilly et al 10 showed that 6q23-q26 deletion is a negative prognostic factor in follicular NHL. Patients with tumors exhibiting this abnormality had a higher risk of transformation of their disease into high-grade lymphoma and significantly shorter survival times. Whang-Peng et al 11 found an association between 6q deletions and shorter survival in NHL without the translocation t(14;18). Oscier et al 12 in their single center chromosome banding analysis found a shorter treatment-free survival for B-CLL patients with abnormalities involving 6q. However, in the large multicenter banding study compiled by the IWCCLL no adverse prognostic effect of 6q deletions was found. 7 To evaluate the incidence and clinical significance of 6q deletions in B-CLL we performed an interphase cytogenetic study applying FISH in 285 patients. Considering that the critical region of 6q deletions in B-CLL has not yet been established we used probes mapping to both NHL deletion regions in bands 6q21 and 6q27.
Methods

Patients
Between August 1990 and July 1997 peripheral blood, bone marrow or splenic tissue specimens were obtained from 285 patients with B-CLL diagnosed according to established criteria. 13 The median time from diagnosis to study was 19 months. Radiotherapy or chemotherapy was administered prior to the study in 12 and 84 patients, respectively. Treatment regimens were heterogeneous. Among the 182 cases diagnosed after August 1990 the median time from diagnosis to study was 6 months (range 0-69 months). Immunophenotypic data were available for 274 of the 285 B-CLL studied; all cases analyzed were CD19
+ , 253 of 268 tested were CD5 + and 255 of 266 were CD23
+ . None of the B-CLL included in this analysis carried the t(11;14)(q13;q32) as detected by our interphase cytogenetic probe set.
14 Mononuclear cells were obtained by Ficoll density gradient centrifugation and harvested either directly or after 3 to 5 day culture as previously described. 15 FISH was performed to detect deletions in B-CLL as previously described. 16, 17 Internal control probes to assure a high hybridization efficiency and cut-off levels for the diagnosis of deletions were applied as described. 16 Signal number was enumerated in 200 nuclei. Probes were generated by Alu-PCR from YACs 963d6 and 977e10 (CEPH YAC library, Généthon, Paris, France). 18 YAC 977e10 is located at the centromeric border of a minimal deletion region in band 6q27 recently identified by molecular genetic techniques in NHL and contains markers AFMa155td9 to D6S1377. 19 YAC 963d6 is located between markers D6S301 and D6S404 in band 6q21 within a deletion region recently found in two B-CLL cases. 20 YAC 963d6 corresponds to YAC 856e1 (CEPH, Généthon) containing marker D6S246 which is immediately telomeric of marker D6S447 where a 2 Mb minimal region of loss was recently identified in NHL by molecular cytogenetics. 21 
Data management and statistical analysis
Clinical and laboratory data of the patients were collected in a database (4th dimension, ACI, Neufahrn, Germany). Lymph node involvement was measured as previously described. 14 Comparison of parameters between patients with and without 6q deletions were performed using the Wilcoxon rank sum test for quantitative variables and Fisher's exact test for binary variables. Survival and censored waiting times were measured from the time of diagnosis and plotted using Kaplan-Meier estimates. Differences between the curves were analyzed by the log-rank test. 22 The proportional hazards regression model of Cox was used for the multivariate analysis of survival time data. 23 All statistical analyses were performed using the software packages S-Plus (MathSoft, Seattle, WA, USA) and StatXact (Cytel Software, Cambridge, MA, USA).
Results
To define a diagnostic threshold for the detection of deletions in B-CLL, the two YAC probes were hybridized on specimens from five healthy probands. The mean percentages of cells exhibiting only a single hybridization signal for YAC 963d6 and 977e10 were 1.6% and 1.4% with standard deviations of 1.0% and 0.7%, respectively. Diagnostic cut-off levels for the detection of deletions in B-CLL samples were therefore calculated at 4.4% and 3.7%, respectively (mean plus three times the standard deviation).
In an initial series of 208 B-CLL both YAC probes were used, ie the tumor cells were screened for deletions in 6q21 and 6q27. Eighteen of the 208 B-CLL studied showed 6q deletions. All 18 deletions were found by YAC 963d6 mapping to 6q21 while the 6q27 region recognized by 977e10 was deleted only in six of these cases and was disomic in the remaining 12 cases. No B-CLL exhibiting a 6q27 deletion without a 6q21 loss was observed. Therefore, the screening in 6q27 was discontinued and only 6q21 was analyzed with YAC 963d6 in the remaining cases. In the entire series of 285 B-CLL, 6q21 deletions were detected in 21 cases (7%). The percentage of cells carrying the deletions ranged from 34% to 93% with a median of 69%. No biallelic deletion was observed.
Among the 285 B-CLL patients analyzed in this study 106 were female and 179 were male; the age at the time of diag- /l vs 31.7 × 10 9 /l; P = 0.036) and more lymphadenopathy as assessed by the sum of the products of the diameters of the largest cervical, axillar and inguinal lymph nodes (median 7.3 cm 2 vs 3.0 cm 2 ; P = 0.029) as well as the largest lymph node diameter (median 4.0 cm vs 2.0 cm; P = 0.008). As illustrated in Figure 1 , the treatment-free intervals defined as the time from diagnosis to first treatment were not significantly different between the two groups (median 43 months vs 41 months; P = 0.26). Figure 2 shows the survival probabilities of the 285 B-CLL patients with (n = 21) or without (n = 264) 6q deletions measured from the time of diagnosis. The median survival time from the date of diagnosis was 131 months for patients with 6q deletions as compared to 132 months for patients without 6q deletions (n = 285; P = 0.86). A separate analysis for the patients diagnosed after August 1990 (n = 182) showed no significant difference in survival probability when comparing patients with (n = 11) and without (n = 171) 6q deletion (P = 0.88). By Cox's proportional hazards regression analysis with survival as dependent variable 6q deletion was not identified as a factor of prognostic impact (P = 0.90).
Discussion
In this interphase cytogenetic study we evaluated the incidence, localization and clinical significance of 6q deletions in 285 patients with B-CLL. Deletions involving 6q were found in 7% of the cases, which is comparable to the 6% incidence of structural 6q aberrations observed in one of the largest B-CLL chromosome banding studies. 7 In contrast to other genomic regions such as 13q14, 11q22-q23, 12q13 or 17p13 interphase FISH did not reveal a higher frequency of 6q aberrations in B-CLL than chromosome banding studies. 8 Despite the fact that the probes used for FISH screening in the current study were carefully selected from minimal deletion regions recently established in NHL, [19] [20] [21] one cannot exclude that a somewhat higher incidence of aberrations would have been found if more probes had been used. The present study could not confirm the high frequency of 6q deletions reported in a small series of B-CLL by FISH. 9 Our results are consistent with data recently reported by Merup et al, 20 who observed 6q deletions in two of 32 B-CLL (6%) tested. The low frequency of 6q deletions in B-CLL as compared to other subsets of NHL underlines the biological differences among the histologic subgroups of NHL. Of particular interest is the contrast to the high incidence of 6q deletions in small lymphocytic NHL which often is considered the non-leukemic counterpart of B-CLL. 
Figure 1
Treatment-free intervals for 285 B-CLL patients with (n = 21) or without (n = 264) 6q deletions. The median time from diagnosis to initiation of treatment was 41 months for patients with 6q deletion as compared to 43 months for the patients without 6q deletion (P = 0.26). 6q27 in our study, ie deletions in B-CLL appear to cluster in the proximal 6q NHL deletion region. 3 We cannot exclude that a higher incidence of 6q27 deletions may have been found if a probe had been used which mapped within the minimal deletion region recently identified in 6q27 19 rather than to the centromeric border of this region. However, a proximal location of the commonly deleted region of 6q in B-CLL was also indicated by chromosome banding studies which found bands 6q15 and 6q23 most frequently involved in B-CLL, 7 and by molecular genetic analyses. Merup et al 20 observed a minimal deletion region spanning at least markers D6S283 to D6S270, containing the genomic region of YAC 963d6, while marker D6S281 mapping to 6q27 was retained. This is in agreement with a study by Gaidano et al 24 who found losses of markers D6S132 and D6S133 mapping to band 6q27 in only four of 100 patients with B-CLL. In a recent
Figure 2
Survival probabilities from the time of diagnosis for 285 B-CLL patients with (n = 21) or without (n = 264) 6q deletion. There is no significant difference between the two curves (P = 0.86).
FISH study Sherratt et al
21 evaluated the extent of 6q deletions in a series of 14 not further specified NHL with 13 YAC probes mapping between bands 6q14 and 6q27. A minimal region of loss defined by potentially overlapping deletions was identified in the 2 Mb interval between markers D6S447 and D6S246 in 6q21 where YAC 963d6 used in the current study is located. However, Sherratt et al 21 found a second region of loss in bands 6q25-q27. In our analysis of 285 B-CLL cases no loss of 6q27 without a deletion in 6q21 could be identified, indicating a clustering of 6q deletions in B-CLL within a single segment which may contain a tumor suppressor gene of pathogenic significance. A candidate gene recently cloned from the critical 6q21 region identified by Sherratt et al 21 is TLX, the human homologue of the Drosophila tailless gene which is a member of the nuclear steroid receptor superfamily. 25 In contrast to the 6q27 NHL deletion region for which a detailed physical map was recently published, 19 the knowledge on candidate genes in 6q21 is still limited and no data are currently available on the potential role of TLX or other genes from this region in the pathogenesis of NHL. The current study is the first molecular cytogenetic analysis of 6q aberrations in a large series of B-CLL and provides the prerequisite for a detailed molecular analysis of 6q deletions. 7 found no adverse prognostic effect of 6q deletions. In our current interphase cytogenetic analysis, although 6q deletions were associated with a higher white blood cell count and more extensive lymphadenopathy, no significant difference in treatment-free survival or overall survival between patients with or without 6q deletion was found. Therefore, despite its association with a higher tumor mass 6q deletion does not appear to be a negative prognostic factor in B-CLL.
